Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
about
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseasePhosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 bindingAKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosisMolecular basis of Pirh2-mediated p53 ubiquitylationHIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic functionDruggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe MoleculesAlterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanismTargeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.Targeting the ubiquitin pathway for cancer treatmentClinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancerLimitations of Peptide Retro-inverso Isomerization in Molecular MimicryAn Ultrahigh Affinity d -Peptide Antagonist Of MDM2mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 InteractionAciculatin induces p53-dependent apoptosis via MDM2 depletion in human cancer cells in vitro and in vivoA synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potentialProbing Difference in Binding Modes of Inhibitors to MDMX by Molecular Dynamics Simulations and Different Free Energy MethodsFunctional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylationThe senescence-associated secretory phenotype: the dark side of tumor suppressionSubstituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.Microarray and ChIP-seq data analysis revealed changes in p53-mediated transcriptional regulation in Nutlin-3-treated U2OS cellsSmall molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.Aberrant regulation of FBW7 in cancer.p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation.High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.Senescent cells as a source of inflammatory factors for tumor progression.Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.Suppression of p53 activity by Siva1Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition.A computational analysis of the binding model of MDM2 with inhibitors.Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.Beta-peptides with improved affinity for hDM2 and hDMX.Virtual screening of low molecular weight mushrooms compounds as potential Mdm2 inhibitors.Mini review: protein-protein interactions in transcription: a fertile ground for helix mimetics.Internalization of p53(14-29) peptide amphiphiles and subsequent endosomal disruption results in SJSA-1 cell death.Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and metastasis through down-regulating MDM2.Mechanisms of small-molecule binding to intrinsically disordered proteins.TP53 loss creates therapeutic vulnerability in colorectal cancer.
P2860
Q24310764-8ECA57D6-BE1B-4FE3-BFB7-C8F73CB80AFEQ24313228-14876ADD-6A14-4BC0-80DE-A573CE61ED15Q24314880-310C4969-6306-4DF4-8992-300AFD222CFDQ24319435-0082730B-1E85-4296-A7AC-4B7EB56A6E04Q24338503-7E4050B4-5123-481D-9D15-E91147585068Q24633124-61384428-C397-412F-A20F-4F6299CCBC1EQ24650534-0E90C031-E9E3-4C21-9D36-F46F0583E275Q24681793-F154A595-5C6C-4F13-B6A5-5076FDD52E90Q24814753-41B50ABA-2317-4806-86AC-10B7A4362A9BQ26866185-9CEE5CDC-970B-4311-980B-7EED1E9490CBQ27002356-70DFBF7A-6627-479F-9FDA-B6716D654943Q27660480-A5B58289-2239-4752-A2F4-5C243EA157FCQ27681154-D541B2EA-9895-4D96-8C35-D6F927D47CC6Q28386936-01DFA9A9-8384-4E27-8B7C-8606490F8FFFQ28482222-94D4E30D-D1F2-4C15-B18F-8B2CB1F20DBDQ28485503-D0FF460B-54FD-4DC1-82F5-41EB5AA59658Q28487720-D9C560B6-CA81-47F3-993A-2F4444F45FDFQ28550543-BFB433F6-7831-4FDB-AACB-4F61829EDD9BQ29248201-251101E0-779F-4E8F-84F4-9261FCE7ED4BQ29620106-6F42D02D-E67F-4685-A77E-2BE373D6CE95Q30353862-A3A8A95E-9B3A-4BB6-8003-89E433EC9D89Q30973420-D5259159-5AE9-40E1-A16D-14E232810991Q33209208-9A86648E-D7C0-4C85-BB1C-D56C20AD124DQ33635059-9052E11F-199B-4BC5-8E92-B2911BD8FF96Q33688508-F99F3EAF-F0D4-45A7-A050-970B527E428FQ33734522-E6F76E46-02F4-4372-B286-E033D7851C76Q33765623-A35031E4-184B-46A3-B76E-DCAA3BB2FC9AQ33833881-DAC5FAF8-6D58-49E7-9B13-9A28B3812364Q33893910-84F4E97A-06AB-4B93-A3E7-4CBD75B5F0BCQ33906122-C54D90C5-FFBA-402E-A8CB-E4EAC899D547Q33998827-F57DA421-141D-4A99-90A8-97067FC80963Q34010186-70B5159B-46CB-4F28-8543-C8B9565E0860Q34063712-6187505D-9403-4A72-B45C-ADCE537CB6B2Q34080613-01E6CBA9-24A1-4148-BD16-C90A19F36B59Q34180483-97864B32-DDEB-468D-8422-0724CE095715Q34253106-E91630AF-AB8E-4929-897E-DE1F605BCFBEQ34384768-3EB67EEF-F203-4CF2-B75B-5152605B2A56Q34388038-172D35DE-063C-4148-ADE9-F83E7648AE0EQ34417638-6B0D631A-D918-4C73-91B0-FA582BC5A4EDQ34473071-1E5CDC5B-8503-4700-A177-0FB31D3F2EFA
P2860
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
@ast
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
@en
type
label
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
@ast
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
@en
prefLabel
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
@ast
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
@en
P2860
P356
P1476
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
@en
P2093
Patrick Chène
P2860
P2888
P304
P356
10.1038/NRC991
P407
P577
2003-02-01T00:00:00Z